Crossmark

Durvalumab and T-DXd Synergistically Promote Apoptosis of Cholangiocarcinoma Cells by Downregulating EGR1 Expression Through Inhibiting P38 MAPK Pathway

Crossref DOI link: https://doi.org/10.1007/s12010-024-05112-0

Published Online: 2024-11-28

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Yuepeng
License Information

Text and Data Mining valid from 2024-11-28

Version of Record valid from 2024-11-28
More Information

Article History

Accepted: 19 November 2024

First Online: 28 November 2024

Declarations

:

: This study was approved by the Ethics Committee of Liaoning Cancer Hospital and Institute (approval number: 20230450). This study was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. All methods were carried out in accordance with relevant guidelines and regulations.

: Not applicable.

: The author declares no competing interests.

Document is current

Any future updates will be listed below